• Integrated treatment of uterine fibroids in women of reproductive age with metabolic disorders 
To content

Integrated treatment of uterine fibroids in women of reproductive age with metabolic disorders 

HEALTH OF WOMAN. 2016.7(113):135–137 

Integrated treatment of uterine fibroids in women of reproductive age with metabolic disorders 

Makarchuk O., Abdulrahman Abdulbaset Moslem

Ivano-Frankivsk national medical University

Uterine cancer is the most common form of benign proliferative processes hormone myometrium and occurs in 20–40% of women of reproductive age and 60% – perimenopausal age. This item as one of the most common diseases of the female reproductive system is dedicated to the many scientific papers and research, but it continues to attract the attention of researchers in the field of medicine. In the literature reports recent years, the experience of using drugs selectively modulating progesterone receptors and inhibiting the growth of units fibroids without affecting the cells of normal myometrium.

The objective: improving the treatment of patients with uterine cancer and obesity using selective modulators of progesterone receptors.

Patients and methods. Special clinical studies included a deep study of anamnestic and clinical data, especially the results of laboratory and instrumental performance, these histological examination. In our studied 60 patients with uterine leiomyoma and obesity treated as preoperative preparation of two hormone treatment programs. The first study group consisted of 30 patients with uterine leiomyoma and excessive body weight and obesity, the treatment program which included selective modulators of progesterone receptors. The second study group were 30 women with hyperplastic processes of cancer and obesity, which was scheduled drugs agonists of gonadotropin-releasing hormone. The control group consisted of 20 patients, preoperative preparation which meet generally accepted standards of clinical and laboratory testing for this type of surgery. To eliminate and reduce the clinical manifestations of side effects associated with the effect of the means data and to correct the dyslipidemia which accompanies metabolic disorders in this category are women, and a positive effect on metabolic and psycho-emotional status, in combination hormone therapy was additionally appointed drug dry extract creeping herb – Тribulus terrestris L.

Results. The results of our investigation both schemes preoperative conservative treatment helped reduce the maximum size weighty fibromatous nodes. Reduced uterine bleeding accompanied by normalization of hemoglobin levels in 3 months in 93.33% of cases the use of selective progesterone receptor modulators against 56.66% using GnRH-a. As for side effects, the most statistically significant difference was in the percentage of vasomotor symptoms. Thus, the proportion of patients who have moderate or marked expressed tides, was 6.6% – in the first group, compared with 36.6% – in the group, which included a medical program-GnRH. Also in the analysis of the therapeutic effect observed statistical average increase in total cholesterol and dyslipidemia deepening in the group using GnRH-a.

Conclusions. Thus, our results of research have shown that the use of SMRP uliprystal acetate are more effective than injections of GnRH-and not only as a preoperative preparation, but also as monotherapy uterine fibroids, especially in patients with metabolic disorders.

Key words: uterine fibroids, obesity, selective progesterone receptor modulators, agonists of gonadotropin-releasing hormone side effects.


1. Tatarchuk TF, Kosei NV, Mogilevsky DM, Sukhorebraya YeI, Shakalo IN. 2006. Aspects of Organ-Preserving Treatment of Uterine Leiomyoma. Reproductive Woman’s Health 1(25):123-129.

2. Garry R, Shett S, Sutton C. 1999. Whych hysterectomy? A detailed Comprasion of Laparoscopic, Vaginal and Abdominal Hysterectomy. Menorrhagia. Iss Medical Media Ltd:239-252.

3. Potapov VO, Medvedyev MV, Donska YuV, Ruban NK. 2012. Predicting Recurrence of Uterine Leiomyoma and Effectiveness of Various Methods of Organ-Preserving Treatment. Medical Prospects 17(4):44-48.

4. Solskiy YaP, Tatarchuk TF, Kosei NV, Lutsenko SI. 2001. Experience with Gonadotropin-Releasing Hormone Usage in Treatment of Uterine Fibroids. Women's Health 1:40-45.

5. Donnez J, Tatarchuk TF, Bouchard P. 2012. PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery 366:409-420.

6. Sabry M. 2012. Innovative Oral Treatments of Uterine leiomyoma Obstetrics Gynecology International. 1-10.

7. Kosei NV. 2008. Phytotherapy in the Treatment of Dishormonal Benign Breast Diseases in Women with Uterine Leiomyoma. Reproductive Woman’s Health 4(38):171-173.

8. Vancov SA. 1996. A Propos of Trіbestan Pharmacology. J. Immunol. 15:4027-4034.